MXCT News and Press, MaxCyte Inc. From 01/24/22

Fourth quarter 2021 revenue expected to be greater than $10 million Full year 2021 revenue expected to be greater than $33.7 million Installed base of greater than 500 instruments 15 SPLs, covering more than 95 programs, of which over 15% have enter...

Cell-based therapies developer MaxCyte (MXCT) made a stellar stock market debut in July last year. However, the stock has lost more than 30% since then, closing yesterday’s trading session at $10.84. With poor financials and profit margins, will MXCT recover this year? Read more to fin...

MaxCyte, Inc. (MXCT) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Sean Menarguez - Investor Relations Douglas Doerfler - Chief Executive Officer Amanda Murphy - Chief Financial Officer Conference Call Participants Julie Simmonds - Panmure Gordon Max Masuc...

GAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discov...

Image source: The Motley Fool. MaxCyte, Inc. (NASDAQ: MXCT) Q3 2021 Earnings Call Nov 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: MaxCyte, Inc. (MXCT) Q3 2021 Earnings Call Transcript

MaxCyte (NASDAQ:MXCT): Q3 GAAP EPS of -$0.03 beats by $0.03. Revenue of $10.1M (+49.4% Y/Y) beats by $2.82M. Press Release FY21 guidance: Revenue is expected to be at least $33M. For further details see: MaxCyte EPS beats by $0.03, beats on revenue

GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discov...

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic disc...

GAITHERSBURG, Md., Oct. 29, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discov...

SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Nkarta, Inc....